Ovensa Inc. appoints Neil Klompas to its Board of Directors
AURORA, ONTARIO, February 3rd, 2017 – Ovensa Inc., a preclinical stage company that capitalizes on its proprietary TRIOZAN™ Nanomedicine Delivery Platform to improve drugs’ efficacy and safety profile, announces that Mr. Neil Klompas, has been appointed to Ovensa’s Board of Directors.
“Neil brings over 20 years of knowledge and experience from the healthcare and biotechnology industry that is complementary to the current board members’ backgrounds. His expertise in raising capital and developing relationships with leading global pharmaceutical companies will certainly contribute to Ovensa’s growth”, said Stephane Gagne, Ovensa’s founding President & CEO.
Mr. Klompas currently serves as the Chief Financial Officer of Zymeworks Inc., a clinical stage biotechnology company developing fit-for-purpose, multifunctional therapeutics for oncology. Prior to joining Zymeworks Mr. Klompas worked with KPMG LLP in the United States, within KPMG’s Pharmaceuticals, Biotechnology and Medical Device M&A Transaction Services practice in Princeton, New Jersey, where he advised on numerous transactions including mergers, acquisitions, divestitures and strategic alliances. Prior to that, Mr. Klompas worked with KPMG’s Canadian Biotechnology and Pharmaceuticals practice. Mr. Klompas is a Chartered Professional Accountant and is a member of Chartered Professional Accountants of British Columbia. Mr. Klompas also holds a degree in Microbiology & Immunology from the University of British Columbia and serves on the faculty advisory board for Biotechnology and Chemistry for Camosun College and as a Director for the Canadian Gene Cure Foundation.
“I am truly excited about the potential for Ovensa to position itself as a leader in the field of nanoparticle formulations with potentially broad applications across multiple disease areas” said Mr. Klompas. “I look forward to contributing my knowledge and expertise to Ovensa’s board of directors, and to assisting the management team as they continue to grow the Company through advancing their platforms and product candidates towards the clinic.”
Ovensa Inc. is a Canadian, preclinical stage company that capitalizes on its proprietary TRIOZAN™ Nanomedicine Delivery Platform, with mucosal and brain-barrier crossing properties, to generate advanced nanotherapeutics, that enhance the bioavailability and the targeted intracellular uptake of small molecules and biologics through oral and other routes of administration. Ovensa mainly focuses on oncology. Its development programs also aim at generating validation data in neurodegenerative diseases and antibiotic resistance.
For more information, please communicate with:
Stéphane Gagné, M.Sc.
President & CEO